会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • Anti-diabetic agents and veterinary anti-diabetic agents
    • Antidiabetikafürhumane undtierärztlicheAnwendung。
    • EP0462022A2
    • 1991-12-18
    • EP91401623.3
    • 1991-06-17
    • CHIBA FLOUR MILLING CO. LTD.Soma, Gen-IchiroMizuno, Den'Ichi
    • SOMA, GEN'ICHIROYOSHIMURA, KIYOSHITSUKIOKA, DAISUKEMIZUNO, DEN'ICHI,OSHIMA, HARUYUKI
    • A61K37/20A61K35/78A61K35/74
    • A61K36/06A61K36/02A61K36/07A61K36/899Y02A50/473A61K2300/00
    • An anti-diabetic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro, and plotting the macrophage activation abillty (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, diabetes mellitus of said animal is prevented or cured; and
         a method of treating diabetes mellitus of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the diabetes mellitus of said animal.
    • 一种抗糖尿病组合物,其包含有效量的至少一种LPS成分,其巨噬细胞活化ED 50为0.4-100ng / ml培养液,其鲎试验阳性LPS含量在通过测定能力制备的乙状曲线上观察到 的LPS以激活体外培养的巨噬细胞的TNF生产力,并绘制沿纵坐标轴的巨噬细胞活化能力(%),其中在对应于由TNFα产生的TNF的量的情况下,该能力估计为0% 没有添加LPS的巨噬细胞,100%被赋予巨噬细胞活化能力,其提供由巨噬细胞产生的TNF的最大和恒定量,并沿着横坐标绘制LPS的鲎试验阳性LPS含量为对数 与药物或兽医学上可接受的载体混合,使得当施用于动物时,预防所述动物的糖尿病或c ured; 以及治疗动物糖尿病的方法,包括向所述动物施用一定量的有效预防或治愈所述动物糖尿病的上述组合物。
    • 8. 发明公开
    • Anti-herpes agents and veterinary anti-herpes agent
    • 反人类和人性化的Anwendung。
    • EP0462020A2
    • 1991-12-18
    • EP91401621.7
    • 1991-06-17
    • CHIBA FLOUR MILLING CO. LTD.Soma, Gen-IchiroMizuno, Den'Ichi
    • Soma,Gen'IchiroYoshimura, KiyoshiTsukioka, DaisukeMizuno Den'IchiOshima ,Haruyuki
    • A61K37/20A61K35/78A61K35/74
    • A61K36/02A61K36/06A61K36/07A61K36/899Y02A50/473A61K2300/00
    • An anti-herpes composition comprising an effective amount of at l east one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, herpes of said animal is cured; and
         a method of treating herpes of an animal comprising administration to said animal an amount of the above composition effective to cure the herpes of said animal.
    • 一种抗疱疹组合物,其包含有效量的至少一种LPS的成员,其巨噬细胞活化ED 50为0.4-100ng / ml培养液,其鲎试验阳性LPS含量在通过测定能力制备的乙状曲线上观察到 的LPS以激活体外培养的巨噬细胞的TNF生产力,并绘制沿纵坐标轴的巨噬细胞活化能力(%),其中在对应于由TNFα产生的TNF的量的情况下,该能力估计为0% 没有添加LPS的巨噬细胞,100%被赋予巨噬细胞活化能力,其提供由巨噬细胞产生的TNF的最大和恒定量,并且沿着横坐标绘制LPS的鲎试验阳性LPS含量为对数 与药学或兽医学上可接受的载体混合,使得当施用于动物时,所述动物的疱疹被固化; 以及治疗动物疱疹的方法,包括向所述动物施用一定量的上述有效治愈所述动物疱疹的组合物。